Lv7
5000 积分 2021-04-25 加入
Low avidity T cells drive endogenous tumor immunity in mice and humans
1天前
已完结
Genomic mechanisms of transformation from chronic obstructive pulmonary disease to lung cancer
15天前
已完结
Mechanistic links between COPD and lung cancer
15天前
已完结
Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights
28天前
已完结
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
1个月前
已完结
PL04.10 Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial
2个月前
已完结
143P Efficacy and safety of aumolertinib (AUM) with radiotherapy versus concurrent chemoradiotherapy (cCRT) in the treatment of unresectable stage III EGFR-mutant NSCLC: A multicenter, randomized, open-label phase III study (ADVANCE)
2个月前
已完结
OA02.04 A Phase III Study of Rilertinib Versus Gefitinib as First-Line Therapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC
2个月前
已完结
RELAY: Final Overall Survival for Erlotinib + Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC
2个月前
已完结
MA12.04 FLAURA2: Impact of Tumor Burden on Outcomes of 1L Osimertinib ± Chemotherapy in Patients with EGFR-mutated Advanced NSCLC
2个月前
已关闭
皖公网安备34019202002308
